Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Sells 13,272 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 13,272 shares of the company’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $7.42, for a total value of $98,478.24. Following the sale, the general counsel now owns 128,473 shares of the company’s stock, valued at approximately $953,269.66. This represents a 9.36 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Benjamin Jackson also recently made the following trade(s):

• On Monday, January 13th, Benjamin Jackson sold 7,912 shares of Sera Prognostics stock. The shares were sold at an average price of $6.38, for a total transaction of $50,478.56.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The stock was sold at an average price of $7.32, for a total value of $34,601.64.

Sera Prognostics Stock Down 0.2 %

Shares of Sera Prognostics stock opened at $6.60 on Friday. The company has a 50 day moving average price of $7.40 and a 200 day moving average price of $7.31. The firm has a market capitalization of $222.88 million, a P/E ratio of -6.67 and a beta of 0.86. Sera Prognostics, Inc. has a 52 week low of $4.98 and a 52 week high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the previous year, the business posted ($0.23) EPS. As a group, research analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC grew its position in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares during the period. SG Americas Securities LLC purchased a new position in Sera Prognostics during the third quarter valued at approximately $78,000. The Manufacturers Life Insurance Company purchased a new stake in Sera Prognostics in the 2nd quarter worth approximately $68,000. Prime Capital Investment Advisors LLC purchased a new stake in Sera Prognostics during the third quarter worth $104,000. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of Sera Prognostics during the 4th quarter valued at about $113,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.